-
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q1 2022 Results - Earnings Call Transcript
14 May 2022 21:48 GMT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2022 … , and thank you for joining Cumberland Pharmaceuticals First Quarter 2022 Financial Report … a key role in our initial public offering, our business development initiatives and …
-
Cumberland Pharmaceuticals: All-Time Lows Look Deserved
28 May 2020 15:08 GMT
… irony to the fact that Cumberland Pharmaceuticals (CPIX) closed Wednesday at an … $6 — admittedly well below an IPO price of $17. Still, the … cash balance created by the IPO helped keep a floor under … at the time of the IPO, but Ofirmev (basically injectable …
-
Cumberland Pharmaceuticals: One Step Forward Isn't Enough
28 Dec 2018 14:28 GMT
… small-cap specialty pharmaceutical company Cumberland Pharmaceuticals (CPIX) has been a lack … $75 million in a 2009 IPO in part to fund acquisitions … disappointment going back to the IPO: back in 2009, Kazimi had …
-
Cumberland Pharmaceuticals: No Reason To Turn Bullish After Q3
22 Jan 2018 19:49 GMT
To look at Cumberland Pharmaceuticals (CPIX) heading into 2018, an … to a decade after an IPO raised cash so the company … stock out of its post-IPO range: CPIX data by YCharts …
-
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
30 Apr 2021 11:53 GMT
… Biologics, Inc. (NASDAQ: AZYO)
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
Dyadic … (before the market open)
IPOs
Vaccitech plc, a clinical- … and cancer, priced its initial public offering of 6.5 million … cancer, priced its upsized IPO of 7.5 million …
-
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs
16 Oct 2020 11:44 GMT
… CDAK) (listed on Nasdaq Wednesday)
Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX)
Dyne … L401 for infantile malignant osteopetrosis.
IPOs
Irvine, California-based Tarsus … conditions, priced its upsized initial public offering, or IPO, of 5.5 million …
-
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
28 Feb 2020 12:42 GMT
… : CNSP)
Codexis, Inc. (NASDAQ: CDXS)
Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX)
Edesa Biotech … : GLYC) (before the market open)
IPO
Passage Bio, a biotech developing …
-
Antibiotics market is projected to grow at a CAGR of 4.15% by 2033: Visiongain Reports Ltd
27 Feb 2023 15:06 GMT
… .), Amneal Pharmaceuticals LLC, Cipla Ltd., Cumberland Pharmaceuticals, Inc., F. Hoffmann-La Roche … .
In March 2022, AN2 Therapeutics’ IPO raised US$69M to take …